Combining the lack of chromogranins with chronic L-DOPA treatment affects motor activity in mice

• Published in: Cell and tissue research Vol. 380; no. 1; pp. 59 - 66
• Main Authors: Castañeyra-Ruiz, Leandro, Castañeyra, Agustín, González-Santana, Ayoze, Machado, José D., Borges, Ricardo
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2020; Springer; Springer Nature B.V
• Subjects: Amphetamines; Basal ganglia; Biomedical and Life Sciences; Biomedicine; Brain diseases; Catecholamines; Central nervous system diseases; Chromogranins; Dihydroxyphenylalanine; Dopamine; Ethylenediaminetetraacetic acid; Human Genetics; Levodopa; Molecular Medicine; Motor activity; Motor task performance; Movement disorders; Neostriatum; Open-field behavior; Phenols; Proteomics; Regular Article; Rodents; Substantia nigra; Toxicity; Striatum; Catecholamines; Behavior; Adrenal; Substantia nigra
• ISSN: 0302-766X; 1432-0878
• DOI: 10.1007/s00441-019-03159-8

We have tested whether the lack of chromogranins (Cgs) A and B could provoke CNS disorders when combined with an excess of dopamine. We chronically treated (over 6 months) mice lacking both chromogranins A and B (Cgs-KO) with a low oral dosage of L-DOPA/benserazide (10/2.5 mg/kg). Motor performance in the rota-rod test, open field activity, and metabolic cages indicated a progressive impairment in motor coordination in these mice, and an increase in rearing behavior, which was accompanied by an increase in DA within the substantia nigra. We conclude that mild chronic L-DOPA treatment does not produce nigro-striatal toxicity that could be associated with parkinsonism, neither in control nor Cgs-KO mice. Rather, Cgs-KO mice exhibit behaviors compatible with an amphetamine-like effect, probably caused by the excess of catecholamines in the CNS.